Cadila Healthcare has received five observations from USFDA after the inspection of Liva Pharmaceuticals’ injectables manufacturing facility. Liva is a 100 per cent subsidiary of Cadila Healthcare.
“This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market,” Cadila Healthcare said in a filing to the BSE today.
The injectables facility is located at Vadodara. The United States Food and Drug Administration (USFDA) had conducted the inspection from August 20-28. Shares of Cadila Healthcare ended down by 2.45 per cent at Rs 386.75 on the BSE.